- Home
- SGN vs LIXT Comparison
SGN vs LIXT Comparison
Compare SGN & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- LIXT
- Stock Information
- Founded
- SGN 2019
- LIXT 2005
- Country
- SGN United States
- LIXT United States
- Employees
- SGN N/A
- LIXT N/A
- Industry
- SGN
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- SGN
- LIXT Health Care
- Exchange
- SGN Nasdaq
- LIXT Nasdaq
- Market Cap
- SGN 4.1M
- LIXT 4.2M
- IPO Year
- SGN 2023
- LIXT N/A
- Fundamental
- Price
- SGN $0.18
- LIXT $1.62
- Analyst Decision
- SGN
- LIXT
- Analyst Count
- SGN 0
- LIXT 0
- Target Price
- SGN N/A
- LIXT N/A
- AVG Volume (30 Days)
- SGN 4.9M
- LIXT 1.8M
- Earning Date
- SGN 11-25-2024
- LIXT 11-12-2024
- Dividend Yield
- SGN N/A
- LIXT N/A
- EPS Growth
- SGN N/A
- LIXT N/A
- EPS
- SGN N/A
- LIXT N/A
- Revenue
- SGN $576,488.00
- LIXT N/A
- Revenue This Year
- SGN N/A
- LIXT N/A
- Revenue Next Year
- SGN N/A
- LIXT N/A
- P/E Ratio
- SGN N/A
- LIXT N/A
- Revenue Growth
- SGN 218.74
- LIXT N/A
- 52 Week Low
- SGN $0.11
- LIXT $1.31
- 52 Week High
- SGN $2.70
- LIXT $4.42
- Technical
- Relative Strength Index (RSI)
- SGN 42.04
- LIXT 43.04
- Support Level
- SGN $0.18
- LIXT $1.56
- Resistance Level
- SGN $0.29
- LIXT $1.87
- Average True Range (ATR)
- SGN 0.03
- LIXT 0.23
- MACD
- SGN -0.00
- LIXT -0.03
- Stochastic Oscillator
- SGN 18.66
- LIXT 8.33
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.